SEC Comment Letter for GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416) (GALT) — May 18, 2020
GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416)
Date: May 18, 2020 · CIK: 0001133416 · Accession: 0000000000-20-004404
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-238151
Letter
United States securities and exchange commission logo May 18, 2020 Jack W. Callicutt Chief Financial Officer Galectin Therapeutics Inc. 4960 Peachtree Industrial Blvd. Suite 240 Norcross, GA 30071 Re:Galectin Therapeutics Inc. Registration Statement on Form S-3 Filed May 11, 2020 File No. 333-238151 Dear Mr. Callicutt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 18, 2020
Jack W. Callicutt
Chief Financial Officer
Galectin Therapeutics Inc.
4960 Peachtree Industrial Blvd.
Suite 240
Norcross, GA 30071
Re:Galectin Therapeutics Inc.
Registration Statement on Form S-3
Filed May 11, 2020
File No. 333-238151
Dear Mr. Callicutt:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences